NCT03505138.

Methods	Study design: unknown centres; open‐label, parallel individual randomised controlled trial Duration: 52 weeks Setting: unknown
Participants	Population: 120 adults recruited from Spain; baseline characteristics: unknown Inclusion criteria: diagnosis of COPD, re‐admission (2+) in last year, stable 6 weeks before study, ≥ 18 years of age, able to use a tablet to track and monitor for the study Exclusion criteria: does not give consent, inadequate social/family support, phone coverage issues, severe comorbidities
Interventions	Measurements taken at baseline and at 12 months Treatment arms Tablet connected to Internet to send data to pneumologist if alerts an exacerbation
Outcomes	Primary outcomes: re‐admission in patients with COPD Secondary outcomes: ICER, CAT, lung function (FEV₁, FVC, FEV₁/FVC), mortality, biomarker predictor of exacerbation severity, medication compliance, patient and caregiver satisfaction, EQ‐5D
Notes	Funding: Sociedad Espanola de Neumologia y Circugia Toracica Other identifier:NCT03505138; CRONEX3.0